PDCD1 and hepatocellular carcinoma: Anti-PD-1 blockade immunotherapy helps to increase the objective response rates of sorafenib-pretreated patients with HCC to 15%~20%, three times greater than that of the sorafenib-only treatment (5, 8, 9).